<DOC>
	<DOCNO>NCT00748709</DOCNO>
	<brief_summary>This Phase II open-label exploratory trial BIBW 2992 administer patient tumor various histology find possess EGFR and/or HER2 gene amplification , EGFR activate mutation .</brief_summary>
	<brief_title>Phase II Trial BIBW 2992 ( Afatinib ) Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification .</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : There 2 Steps screen process : Step 1 Inclusion criterion prescreening : 1 . Histologically confirm diagnosis advance cancer one follow four tumor type category : Category 1 , Gastric , GE junction , Esophageal cancer Category 2 , Biliary gallbladder cancer Category 3 , TCC urothelial tract , Category 4 , Gynecological cancers 2 . Measurable disease RECIST criterion . 3 . Willingness ability give write informed consent consistent ICHGCP guideline . 4 . Life expectancy least three ( 3 ) month . 5 . Eastern Cooperative Oncology Group performance score 0 , 1 2 . 6 . Age &gt; 18 year . Step 2 Inclusion criterion enrollment : Patients test positive FISH consider candidate trial must meet follow inclusion criterion : 1 . Histologically confirm diagnosis advance cancer one follow four tumor type category : Category 1 , Gastric , GE junction , Esophageal cancer Category 2 , Biliary gallbladder cancer Category 3 , TCC urothelial tract , Category 4 , Gynecological cancers 2 . Documented failure respond progression underlie cancer least one line prior chemotherapy . 3 . EGFR and/or HER2 gene amplification FISH testing patient tumor harbor know activate EGFR mutation . 4 . Measurable disease RECIST criterion . 5 . Willingness ability give write informed consent consistent ICHGCP guideline . 6 . Life expectancy least three ( 3 ) month . 7 . Eastern Cooperative Oncology Group performance score 0 , 1 2 . 8 . Age &gt; 18 year . Exclusion criterion : 1 . Prior treatment gefitinib , erlotinib , lapatinib and/or EGFR TKIs . 2 . Treatment cytotoxic anticancertherapies investigational drug last four week prior first treatment trial drug . ( short duration may consider patient treated oral , non cytotoxic drug individual basis upon discussion principal investigator sponsor ) 3 . Inability take BIBW 2992 mouth ( BIBW 2992 may crush administered via Gastrostomytube ) 4 . Chronic diarrhea gastrointestinal disorder may interfere absorption trial drug . 5 . History malignancy unless free disease least 3 year ( except appropriately treat superficial nonmelanoma skin cancer surgically cure cervical cancer situ ) . 6 . History presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure NYHA classification 3 , unstable angina poorly control arrhythmia . Myocardial infarction within 6 month prior randomization . 7 . Resting leave ventricular ejection fraction &lt; 50 % OR institution 's low limit normal ( institution low limit 50 % ) , measure MUGA scan echocardiogram . 8 . Active infectious disease 9 . Serious illness , concomitant nononcological disease mental problem consider investigator incompatible participation trial . 10 . Active/symptomatic brain metastasis . Patients history treat brain metastasis must stable normal brain MRI scan screening least three month postradiation surgery brain metastasis . 11 . Absolute Neutrophil Count ( ANC ) less 1,000/mm3 . 12 . Platelet count less 100,000/mm3 . 13 . Hemoglobin Level le 9.0 grams/dl . 14 . Total Bilirubin great 1.5 mg/dl ; high Total Bilirubin value may acceptable patient know GilbertÂ¿s disease , approval PI sponsor necessary . 15 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) great 3 time upper limit normal ; 5 time upper limit normal patient neoplastic liver involvement . 16 . Serum creatinine great 1.5 x upper limit normal institution . 17 . Patients sexually active unwilling use simultaneously two medically acceptable method contraception , one barrier type method condom . 18 . Pregnancy breastfeed . 19 . Patients unable comply protocol 20 . Active alcohol and/or substance abuse . 21 . Continuation therapyrelated toxicity prior anti cancer therapy , prior surgery , CTCAE Grade &gt; =2 time first administration trial drug . 22 . Patients know preexist interstitial lung disease . 23 . Requirement treatment prohibit concomitant medication : additional experimental anticancer treatment and/or standard chemotherapy , immunotherapy , hormone treatment radiotherapy ; Pgp inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>